Ozempic Lawsuit 2026: Gastroparesis Claims, MDL Status & Who Qualifies to File

Thousands of lawsuits allege that GLP-1 weight-loss and diabetes drugs — Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound — caused severe stomach paralysis (gastroparesis), intestinal obstruction, and vision loss. The cases are consolidated in federal multidistrict litigation MDL No. 3094 in the Eastern District of Pennsylvania, where the court is moving the litigation through bellwether proceedings. Compensation varies widely by case, and most settlements are confidential.

The GLP-1 drug class went from niche diabetes treatment to cultural phenomenon in just a few years, with millions of Americans taking semaglutide, tirzepatide, or liraglutide for diabetes or weight loss. But as use exploded, so did reports of severe gastrointestinal injuries — some so serious that patients required hospitalization, feeding tubes, or emergency surgery for blocked intestines. Federal regulators updated the drugs' warning labels to highlight the risk of intestinal blockage (ileus), and litigation followed.

The lawsuits do not claim that the drugs never work. They allege that the manufacturers knew — or should have known — about the severity and persistence of these injuries and failed to warn patients and doctors adequately. If you or someone you love took one of these drugs and suffered a severe gastrointestinal injury or sudden vision loss, here is where the litigation stands in 2026 and who may qualify to file.

For more plain-language explainers on money, insurance, and the law, follow the Problem Solved channel.

What the GLP-1 Litigation Is About

GLP-1 receptor agonists — glucagon-like peptide-1 receptor agonists — slow gastric emptying as part of how they work: food stays in the stomach longer, which reduces appetite. In most patients this is the intended effect. The lawsuits allege that in some patients the effect went far beyond appetite suppression, producing gastroparesis — stomach paralysis in which the stomach cannot empty at all — persistent vomiting, malnutrition, intestinal obstruction, and in some cases a condition called ileus, where the intestines stop moving food through.

A second branch of claims involves vision loss, including a condition called NAION (non-arteritic anterior ischemic optic neuropathy), a sudden loss of vision caused by reduced blood flow to the optic nerve. Plaintiffs allege the manufacturers failed to warn that the drugs were associated with this risk. A detailed breakdown of which drugs are implicated is covered in our comparison of every drug named in the GLP-1 MDL.

The MDL: Where the Cases Stand in 2026

The federal cases are centralized in multidistrict litigation MDL No. 3094 before the U.S. District Court for the Eastern District of Pennsylvania, consolidated in February 2024. An MDL — multidistrict litigation — is a procedural device that moves hundreds or thousands of similar federal lawsuits to one judge for coordinated pretrial proceedings: shared discovery, expert-witness battles, and rulings that apply across cases. Each plaintiff keeps an individual case; the MDL is not a class action.

The MDL covers claims involving six products: Ozempic, Wegovy, and Rybelsus (semaglutide, made by Novo Nordisk) and Trulicity (dulaglutide), Mounjaro, and Zepbound (tirzepatide, made by Eli Lilly). The court is working through the bellwether process — a sequence of representative cases selected for early trial. Bellwether verdicts do not decide every case, but they give both sides critical information about how juries value these injuries, which often drives settlement negotiations across the whole MDL. For the vision-loss track specifically, see our guide to Ozempic vision-loss claims and NAION lawsuits.

The Injuries at the Center: Gastroparesis and Intestinal Obstruction

Gastroparesis — literally "stomach paralysis" — means the stomach's muscular contractions slow or stop, so food sits undigested for days. Symptoms include severe nausea, repeated vomiting, abdominal pain, bloating, and in extreme cases malnutrition and dehydration requiring hospitalization. Diagnosis typically comes from a gastric emptying study. What makes these claims legally significant is persistence: some plaintiffs allege their gastroparesis continued long after they stopped the drug.

Intestinal obstruction cases are the most acute. An obstructed bowel is a medical emergency — patients present with severe abdominal pain, inability to pass gas or stool, and vomiting, and treatment can require emergency surgery. Regulators updated the Ozempic label to warn of ileus risk after post-marketing reports accumulated, which plaintiffs cite as evidence the companies were on notice. Our dedicated guide to Ozempic intestinal-blockage claims and the FDA warning walks through that regulatory history in detail.

Who Qualifies to File a Claim

Eligibility is not determined by simply having taken the drug. Mass-tort firms generally screen for three elements: documented use of one of the named GLP-1 drugs, a qualifying injury diagnosis — gastroparesis confirmed by testing, intestinal obstruction or ileus requiring medical treatment, or sudden vision loss diagnosed as NAION — and medical records connecting the timeline. Emergency-room visits, hospitalizations, feeding tubes, and surgeries strengthen a claim because they document severity.

Two filters routinely exclude potential filers. First, the statute of limitations: every state sets its own deadline for product-liability claims, typically two to three years from when you knew or should have known of the injury, and missing it ends the case permanently. Second, pre-existing conditions: patients who already had diagnosed gastroparesis, prior bowel obstructions, or unrelated optic-nerve disease before starting the drug face an uphill causation fight. An honest intake lawyer will tell you this upfront — beware any firm that accepts your case without reviewing your records.

What to Do Before You Call a Lawyer

Start by preserving your records while they are fresh. Request your complete pharmacy records showing the drug, dosage, and dates of use, and your medical records from every provider who treated the injury — ER, gastroenterologist, surgeon, ophthalmologist. Write down your timeline: when you started the drug, when symptoms began, what treatments you received, and whether symptoms persisted after stopping. Photographs of medication bottles and discharge paperwork help too.

When evaluating a law firm, ask three questions: whether the firm is admitted in the MDL or partnered with a firm that is, whether the case will be filed individually in the MDL (it should be — this is not a class action), and how fees work. Reputable mass-tort firms work on contingency — no upfront fee, with the firm taking an agreed percentage of any recovery plus case costs. For help choosing counsel, read our guide to choosing an Ozempic lawyer in 2026. And remember: compensation varies widely by case, and most settlements are confidential — no lawyer can promise you a number at intake.

Key Facts

  • The GLP-1 lawsuits are consolidated as MDL No. 3094 in the Eastern District of Pennsylvania, centralized in February 2024.
  • The MDL covers Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, and Zepbound.
  • Core alleged injuries are gastroparesis (stomach paralysis), intestinal obstruction or ileus, and vision loss including NAION.
  • The court is moving through bellwether proceedings — representative early trials that shape settlement expectations across the MDL.
  • An MDL is not a class action: each plaintiff retains an individual case with an individual outcome.

Who Benefits From This — and Who Does Not

Who benefits most from this guide:

Patients with a diagnosed severe injury after GLP-1 use. How: Firms generally look for diagnosed gastroparesis, intestinal obstruction or ileus requiring medical treatment, or sudden vision loss such as NAION, with medical records showing the drug was used before the injury appeared.

Patients who used one of the six MDL drugs. How: The MDL, No. 3094 in the Eastern District of Pennsylvania, covers Ozempic, Wegovy, and Rybelsus (semaglutide) and Trulicity (dulaglutide), Mounjaro, and Zepbound (tirzepatide), against manufacturers Novo Nordisk and Eli Lilly.

Patients who act within their state’s window. How: Product-liability statutes of limitations are typically two to three years from when the injury was discovered or should have been discovered: speaking with a lawyer promptly matters more than waiting for the MDL to resolve.

Who does not benefit:

Patients with mild nausea alone do not typically benefit from a claim: mild nausea alone does not typically support a claim, which centers on severe, medically treated injuries.

Patients who never took a listed GLP-1 drug do not benefit: the MDL covers the six named products, not weight-loss or diabetes drugs generally.

Patients expecting a class-action settlement or a guaranteed amount do not benefit from that expectation: each plaintiff keeps an individual lawsuit and an individual result, bellwether verdicts are not binding on other cases, and most settlements are confidential.

Related reading: our NEC baby formula lawsuit guide.

Frequently Asked Questions

Is the Ozempic lawsuit a class action?

No. The federal cases are in multidistrict litigation (MDL No. 3094), where each plaintiff keeps an individual lawsuit and an individual result. Shared pretrial proceedings make the litigation efficient, but your case is decided on your own facts and injuries.

Which drugs are included in the GLP-1 MDL?

Six products: Ozempic, Wegovy, and Rybelsus (semaglutide), and Trulicity (dulaglutide), Mounjaro, and Zepbound (tirzepatide). Claims involve the drugs' manufacturers, Novo Nordisk and Eli Lilly.

What injuries qualify for the Ozempic lawsuit?

Firms generally look for diagnosed gastroparesis, intestinal obstruction or ileus requiring medical treatment, or sudden vision loss such as NAION — with medical records showing the drug was used before the injury appeared. Mild nausea alone does not typically support a claim.

How long do I have to file an Ozempic lawsuit?

It depends on your state. Product-liability statutes of limitations are typically two to three years from when you discovered (or should have discovered) the injury. Because the clock may already be running, speaking with a lawyer promptly matters more than waiting for the MDL to resolve.

What is a bellwether trial and why does it matter?

Bellwether trials are representative early trials selected from the MDL. Their verdicts are not binding on other cases, but they reveal how juries evaluate the evidence and value these injuries — information both sides use to negotiate settlements for the remaining cases.

Who benefits most from the Ozempic lawsuit in 2026?

Patients benefit most with a diagnosed severe injury after GLP-1 use: diagnosed gastroparesis, intestinal obstruction or ileus requiring treatment, or sudden vision loss such as NAION, with records showing drug use before the injury. Patients who used one of the six MDL drugs also benefit, as do patients who act within the typical two-to-three-year discovery window.

Who does not qualify for the Ozempic lawsuit?

Patients with mild nausea alone do not typically qualify, since claims center on severe, medically treated injuries. Patients who never took a listed drug, Ozempic, Wegovy, Rybelsus, Trulicity, Mounjaro, or Zepbound, do not qualify, and neither do patients expecting a class-action payout or a guaranteed amount, since each case is individual.

How do I start an Ozempic lawsuit claim?

Collect prescription records showing which GLP-1 drug you took and when, plus medical records showing the injury and that the drug was used before the injury appeared. Note the date you discovered the injury, since the typical two-to-three-year clock runs from discovery, and speak with a lawyer promptly rather than waiting for the MDL bellwether trials to conclude.

Disclaimer: This article is for general information only and is not legal or financial advice. Laws, policies, and figures change over time — verify current rules with a qualified professional before acting.

Watch on YouTube

Problem Solved on YouTube